skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Viagenpumatucel-L (Code C61073)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Viagenpumatucel-L

Definition: A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1.

Label: Viagenpumatucel-L

NCI Thesaurus Code: C61073 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831778  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Gp96-Ig Fusion Protein-Expressing Non-Small Cell Lung Cancer Cell Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 473873
PDQ Open Trial Search ID 473873 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831778

Other Properties:
     Name Value (qualifiers indented underneath)
code C61073
Legacy_Concept_Name Gp96-Ig_Fusion_Protein-Expressing_Non-Small_Cell_Lung_Cancer_Cell_Vaccine
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom